EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

Deliang Guo, Robert M. Prins, Julie Dang, Daisuke Kuga, Akio Iwanami, Horacio Soto, Kelly Y. Lin, Tiffany T. Huang, David Akhavan, M. Benjamin Hock, Shaojun Zhu, Ava A. Kofman, Steve J. Bensinger, William H. Yong, Harry V. Vinters, Steve Horvath, Andrew D. Watson, John G. Kuhn, H. Ian Robins, Minesh P. MehtaPatrick Y. Wen, Lisa M. Deangelis, Michael D. Prados, Ingo K. Mellinghoff, Timothy F. Cloughesy, Paul S. Mischel

Research output: Contribution to journalArticle

167 Citations (Scopus)

Fingerprint Dive into the research topics of 'EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds